Browse > Article

Inhibitory Effects of Bee Venom on Growth of A549 Lung Cancer Cells via Induction of Death Receptors  

Jang, Dong Min (Department of Acupuncture & Moxibustion Medicine, College of Oriental Medicine, Gachon University)
Song, Ho Sueb (Department of Acupuncture & Moxibustion Medicine, College of Oriental Medicine, Gachon University)
Publication Information
Journal of Acupuncture Research / v.30, no.1, 2013 , pp. 57-70 More about this Journal
Abstract
This study was to investigated the effects of the bee venom on inhibition of cell growth via upregulation of death receptor expression in the A549 human lung cancer cells. Bee venom(1-5 ${\mu}g$/ml) inhibited the growth of A549 lung cancer cells by the induction of apoptotic cell death in a dose dependent manner. Consistent with apoptotic cell death, expression of TNFR1, Fas, death receptors(DR) 3, 4 and 6 was increased in the cells. Expression of DR downstream pro-apoptotic proteins including caspase-3, -9 and Bax was concomitantly increased, but the expression of Bcl-2, NF-${\kappa}B$ were inhibited by treatment with bee venom in A549 cells. Moreover, deletion of DR3, DR4 by small interfering RNA significantly reversed bee venom-induced cell growth inhibitory effect, whereas Apo3L strengthened anti-proliferative effect of bee venom through enhancement of DR3 expression. These results suggest that bee venom should exert anti-tumor effect through induction of apoptotic cell death in lung cancer cells via enhancement of death receptor expression, and that bee venom could be a promising agent for preventing and treating lung cancer.
Keywords
Bee venom; Lung cancer; A549; Apoptosis Death receptor;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Jazirehi AR, Ng CP, Gan XH, Schiller G, Bonavida B. Adriamycin sensitizes the adriamycinresistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand(TRAIL)-mediated apoptosis. Clin Cancer Res. 2001 ; 7(12) : 3874-3883.
2 Tillman DM, Izeradjene K, Szucs KS, Douglas L, Houghton JA. Rottlerin sensitizes colon carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via uncoupling of the mitochondria independent of protein kinase C. Cancer Res. 2003 ; 63(16) : 5118-5125.
3 Rothe M, Sarma V, Dixit VM, Goeddel DV. TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science. 1995 ; 269(5229) : 1424-1427.   DOI   ScienceOn
4 Rothe M, Wong SC, Henzel WJ, Goeddel DV. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell. 1994 ; 78(4) : 681-692.   DOI   ScienceOn
5 Hua F, Cornejo MG, Cardone MH, Stokes CL, Lauffenburger DA. Effects of Bcl-2 levels on Fas signaling-induced Caspase-3 activation: molecular genetic tests of computational model predictions, J Immunol vol. 2005 ; 175(2) : 985-995   DOI
6 Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992 ; 10 : 411-452.   DOI   ScienceOn
7 Nagata S. Apoptosis by death factor. Cell. 1997 ; 88(3) : 355-365.   DOI   ScienceOn
8 Marsters S, Sheridan J, Donahue C et al. Apo3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-$\kappa$B. Curr Biol. 1996 ; 6(12) : 1669-1676.   DOI   ScienceOn
9 Chinnaiyan AM, O'ourke K, Yu GL et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 1996 ; 274(5289) : 990-992.   DOI   ScienceOn
10 Kitson J, Raven T, Jiang YP et al. A deathdomain- containing receptor that mediates apoptosis. Nature. 1996 ; 384(6607) : 372-375.   DOI   ScienceOn
11 Bodmer JL, Burns K, Schneider P et al. TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis receptor 1 and Fas(Apo-1/CD95). Immunity. 1997 ; 6(1) : 79-88.   DOI   ScienceOn
12 Screaton G, Xu X, Olsen A et al. LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing. Proc Natl Acad Sci USA 1997 ; 94(9) : 4615-4619.   DOI
13 Golstein P. Cell death: TRAIL and its receptors. Curr Biol. 1997 ; 7(12) : R750-R753.   DOI   ScienceOn
14 Ray S, Almasan A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2ligand/tumor necrosis factorrelated apoptosis-inducing ligand and CPT-11. Cancer Res. 2003 ; 63(15) : 4713-4723.
15 Shankar S, Singh TR, Chen X, Thakkar H, Firnin J, Srivastava RK. The sequential treatment with ionizing radiation followed by TRAIL/ Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice. Int J Oncol. 2004 ; 24(5) : 1133-1140.
16 Sheridan JP, Marsters SA, Pitti RM et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997 ; 277(5327) : 818-821.   DOI   ScienceOn
17 Hannon GJ. RNA interference. Nature. 2002 ; 418(6894) : 244-251.   DOI   ScienceOn
18 Jang MH, Shin MC, Lim S et al. Bee venom induces apoptosis and inhibits expression of cyclooxygenase-2 mRNA in human lung cancer cell line NCI-H1299. J Pharmacol Sci. 2003 ; 91(2) : 95-104.   DOI   ScienceOn
19 Huerta-Yepez S, Vega M, Jazirehi A et al. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene. 2004 ; 23(9) : 4993-5003.   DOI   ScienceOn
20 Liu S, Yu M, He Y et al. Melittin prevents liver cancer cell metastasis through inhibition of the Rac1-dependent pathway. Hepatology. 2008 ; 47(6) : 1964-1973.   DOI   ScienceOn
21 Hengartner MO. The biochemistry of apoptosis. Nature. 2000 ; 407(6805) : 770-776.   DOI   ScienceOn
22 Reed JC. Apoptosis-regulating proteins as targets for drug discovery. Trends Mol Med. 2001 ; 7(7) : 314-319.   DOI   ScienceOn
23 Li JY, Xu ZJ, Tan MY, Su WK, Gong XG. 3-(4-(Benzo[d]thiazol-2-yl)-1-phenyl-1Hpyrazol -3-yl) phenyl acetate induced HepG2 cell apoptosis through a ROS-mediated pathway. Chem Biol Interact. 2010 ; 183(3) : 341-48.   DOI   ScienceOn
24 Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998 ; 281(5831) : 1309-1312.   DOI   ScienceOn
25 Cain K, Brown DG, Langlais C, Cohen GM. Caspase activation involves the formation of the aposome, a large(approximately 700 kDa) caspaseactivating complex. J Biol Chem. 1999 ; 274(32) : 22686-22682.   DOI
26 Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol. 1999 ; 17 : 331-7.   DOI   ScienceOn
27 Old LJ. Tumor necrosis factor. Sci Am. 1988 ; 258(5) : 59-60.   DOI   ScienceOn
28 Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 1994 ; 76(6) : 959-962.   DOI   ScienceOn
29 Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MA, Jr and Goeddel DV. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci USA. 1991 ; 88(20) : 9292-9296.   DOI   ScienceOn
30 Beutler B, van Huffel C. Unraveling function in the TNF ligand and receptor families. Science. 1994 ; 264(5159) : 667-668.   DOI
31 Schutze S, Potthoff K, Machleidt T, Berkovic D, Wiegmann K, Kronke M. TNF activates NF-kappa B by phosphatidylcholine-specific phospholipase C-induced "cidic"c sphingomyelin breakdown. Cell. 1992 ; 71(5) : 765-776.   DOI   ScienceOn
32 Laegreid A, Medvedev A, Nonstad U et al. Tumor necrosis factor receptor p75 mediates cell-specific activation of nuclear factor kappa B and induction of human cytomegalovirus enhancer. J Biol Chem. 1994 ; 269(10) : 7785-7791.
33 Mukhopadhyay A, Suttles J, Stout RD, Aggarwal BB. Genetic deletion of the tumor necrosis factor receptor p60 or p80 abrogates ligandmediated activation of nuclear factor-kappa B and of mitogen-activated protein kinases in macrophages. J Biol Chem 2001 ; 276(34) : 31906-31912.   DOI   ScienceOn
34 Grell M, Becke FM, Wajant H, Mannel DN, Scheurich P. TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1. Eur J Immunol. 1998 ; 28(1) : 257-263.   DOI   ScienceOn
35 Medvedev AE, Espevik T, Ranges G, Sundan A. Distinct roles of the two tumor necrosis factor(TNF) receptors in modulating TNF and lymphotoxin alpha effects. J Biol Chem. 1996 ; 271(16) : 9778-9784.   DOI
36 Zhu DM, Shi J, Liu S, Liu Y, Zheng D. HIV infection enhances TRAIL-induced cell death in macrophage by down-regulating decoy receptor expression and generation of reactive oxygen species. PLoS One. 2011 ; 6(4) : e18291.   DOI   ScienceOn
37 Elrod HA, Sun SY. Modulation of death receptors by cancer therapeutic agents. Cancer Biol Ther. 2008 ; 7(2) : 163-173.   DOI   ScienceOn
38 Yoshida T, Horinaka M, Sakai T. "Combinationoriented molecular-targeting prevention" of cancer: a model involving the combination of TRAIL and a DR5 inducer. Environ. Health Prev. Med. 2010 ; 15(4) : 203-210.   DOI
39 Inoue N, Matsuda F, Goto Y, Manabe N. Role of cell-death ligand-receptor system of granulosa cells in selective follicular atresia in porcine ovary. J Reprod Dev. 2011 ; 57(2) : 169-175.   DOI   ScienceOn
40 Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev. 2008 ; 19(3-4) : 325-331.   DOI   ScienceOn
41 Sun SY. Understanding the role of the death receptor 5/FADD/caspase-8 death signaling in cancer metastasis. Mol Cell Pharmacol. 2011 ;3(1) : 31-34.
42 Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene. 2010 ; 29(34) : 4752-4765.   DOI   ScienceOn
43 Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onsetprogression and therapy. Nat Rev Cancer. 2008 ; 8(10) : 782-798.   DOI   ScienceOn
44 Stegehuis JH, de Wilt LH, de Vries EG, Groen HJ, de Jong S, Kruyt FA. TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives, Drug Resist. Updates. 2010 ; 13(1-2) : 2-5.   DOI   ScienceOn
45 Van Geelen CM, de Vries EG, de Jong S. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updates. 2004 ; 7(6) : 345-358.   DOI   ScienceOn
46 Abdulghani J, El-Deiry WS. TRAIL receptor signaling and therapeutics, Exp Opin Therapeut Targets. 2010 ; 14(10) : 1091-1108.   DOI   ScienceOn
47 Park JH, Jeong YJ, Park KK et al. Melittin suppresses PMA-induced tumor cell invasion by inhibiting NF-kappaB and AP-1-dependent MMP-9 expression. Mol Cells. 2010 ; 29(2) : 209-215.   DOI   ScienceOn
48 Jin CY, Park C, Hwang HJ et al. Naringenin up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer A549 cells, Mol. Nutr Food Res. 2011 ; 55(2) : 300-309.   DOI   ScienceOn
49 Lu M, Strohecker A, Chen F et al. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels, Clin. Cancer Res. 2008 ; 14(10) : 3168-3176.   DOI   ScienceOn
50 Park HJ, Lee SH, Son DJ et al. Antiarthritic effect of bee venom: inhibition of inflammation mediator generation by suppression of NFkappaB through interaction with the p50 subunit. Arthritis Rheum. 2004 ; 50(11) : 3504-3515.   DOI   ScienceOn
51 Park MH, Choi MS, Kwak DH et al. Anticancer effect of bee venom in prostate cancer cells through activation of caspase pathway via inactivation of NF-Κ$\beta$. Prostate. 2011 ; 71(8) : 801-812.   DOI   ScienceOn
52 Ginsber RJ, Kris MK, Armstrong JG. Cancer of the lung in Principles and Practice of Oncology, 4th ed(DeVita DT Jr, Hellman S, Rosenberg SA eds). Philadelphia PA : Lippincott-Raven Publishers. 1993 ; 673-682.
53 Jemal A, Siegel R, Ward E et al. Cancer statistics. CA Cancer J Clin. 2008 ; 58(2) : 71-96.   DOI   ScienceOn
54 de Petris L, Crino L, Scagliotti GV et al. Treatment of advanced non-small cell lung cancer. Ann Oncol. 2006 ; 2 : 1136-1141.
55 Giaccone G. Clinical perspectives on platinum resistance. Drugs. 2000 ; 59(4) : 9-17.
56 Fadeel B, Orrenius S. Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J Int Med. 2005 ; 258(6) : 479-517.   DOI   ScienceOn
57 Kang YJ, Kim IY, Kim EH et al. Paxilline enhances TRAIL-mediated apoptosis of glioma cells via modulation of c-FLIP, survivin and DR5. Exp Mol Med. 2011 ; 43(1) : 24-34.   DOI
58 Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 2005 ; 55(3) : 178-194. 71-96.   DOI   ScienceOn
59 Costantini P, Jacotot E, Decaudin D, Kroemer G. Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst. 2000 ; 92(13) : 1042-1053.   DOI   ScienceOn
60 O'Donovan TR, O'Sullivan GC, McKenna S. Induction of autophagy by drugresistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics. Autophagy. 2011 ; 7(5) : 509-524.   DOI
61 Gruss HJ, Dower SK. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood. 1995 ; 85(12) : 3378-3404.